CVE-2026-56402NanoClaw before 2.1.17 contains a privilege escalation vulnerability in the handleApprovalsResponse function that fails to verify responder role authorization.
Updated under an hour ago ()
Does this affect you?
It lists no affected products yet. Add what you run and Signals checks it as products are added.
No exploitation reported and no EPSS estimate yet.
NanoClaw before 2.1.17 contains a privilege escalation vulnerability in the handleApprovalsResponse function that fails to verify responder role authorization. Attackers with a valid questionId can approve or reject privileged actions like package installation by submitting approval response payloads without proper role validation.
- CVSS
- 6.5 MEDIUM (v3.1, NVD)CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:H/A:N
- Weakness (CWE)
- CWE-862
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- Not loaded for this CVE
- Assigned by
- Not given
- NVD analysis
- Deferred
- Record last updated
- Sep 17, 2026
- First seen by InfoSec Signals
- Oct 9, 2026
Affected products
No affected products are listed yet.
References
- https://github.com/nanocoai/nanoclaw/commit/6227bd1a5b016fb1eb76411bb6681b4c924a51a0
- https://github.com/nanocoai/nanoclaw/pull/2478
- https://www.vulncheck.com/advisories/nanoclaw-privilege-escalation-via-unverified-approval-response-handler
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.